Jun 21, 2019

Gensight Biologics Releases Data, CFO Responds to LEAF Inquiry

Posted by in categories: biotech/medical, genetics, life extension

Gensight Biologics, a company researching – among other things – the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research Foundation), has recently released data for its latest trial of GS010, a therapy against the blindness-causing genetic disease LHON.

Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT).

Comments are closed.